TREATMENT OF STROKE AND OTHER ACUTE NEURAL DEGENERATIVE DISORDERS USING POSTPARTUM-DERIVED CELLS
First Claim
1. A pharmaceutical composition for treating a patient having an acute neurodegenerative condition, comprising a pharmaceutically acceptable carrier and postpartum-derived cells in an amount effective to treat the neurodegenerative condition wherein the postpartum-derived cells are derived from umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- wherein the cells require L-valine for growth and can grow in at least about 5% oxygen;
wherein the cells do not produce CD117; and
wherein the cells further comprise at least one of the following characteristics;
a) potential for at least 40 doublings in culture;
b) production of at least one of tissue factor, vimentin, and alpha-smooth muscle actin;
c) production of at least one of CD 10, CD 13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
d) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ;
e) secretion of at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1a, RANTES, and TIMP1; and
f) lack of secretion of at least one of TGF-beta2, ANG2, PDGFbb, MIP1b, I309, MDC, and VEGF, as detected by ELISA.
6 Assignments
0 Petitions
Accused Products
Abstract
Cells derived from postpartum tissue such as the umbilical cord and placenta, and methods for their use to regenerate, repair, and improve neural tissue, and to improve behavior and neurological function in stroke patients are disclosed.
-
Citations
18 Claims
-
1. A pharmaceutical composition for treating a patient having an acute neurodegenerative condition, comprising a pharmaceutically acceptable carrier and postpartum-derived cells in an amount effective to treat the neurodegenerative condition wherein the postpartum-derived cells are derived from umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- wherein the cells require L-valine for growth and can grow in at least about 5% oxygen;
wherein the cells do not produce CD117; and
wherein the cells further comprise at least one of the following characteristics;a) potential for at least 40 doublings in culture; b) production of at least one of tissue factor, vimentin, and alpha-smooth muscle actin; c) production of at least one of CD 10, CD 13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C; d) lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ; e) secretion of at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1a, RANTES, and TIMP1; and f) lack of secretion of at least one of TGF-beta2, ANG2, PDGFbb, MIP1b, I309, MDC, and VEGF, as detected by ELISA. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- wherein the cells require L-valine for growth and can grow in at least about 5% oxygen;
Specification